Compare GSK plc (GSK) vs TeraWulf Inc (WULF) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

WULF trades at $17.92, down 7.68% in the past 24 hours, with a bearish technical signal and support near $17. The stock shows weak fundamentals with a net loss of $661.42 million in 2025 and negative profit margins, but holds a 100% buy rating from analysts. Recent news highlights a major 20-year, $19 billion AI infrastructure deal with Anthropic, positioning the company in the high-demand data center space.

The outlook is polarized: strong analyst optimism with a $36 consensus price target reflects growth potential from AI partnerships, but high execution risks, negative earnings, and cash burn pose significant challenges. Investors face substantial upside if AI contracts materialize successfully, alongside volatility from operational losses and sector headwinds.